93 related articles for article (PubMed ID: 8643177)
1. Angiotensin-converting enzyme inhibitors and higher erythropoietin requirement in chronic haemodialysis patients.
Dhondt AW; Vanholder RC; Ringoir SM
Nephrol Dial Transplant; 1995 Nov; 10(11):2107-9. PubMed ID: 8643177
[No Abstract] [Full Text] [Related]
2. ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance.
Saudan P; Halabi G; Perneger T; Wasserfallen JB; Wauters JP; Martin PY;
J Nephrol; 2006; 19(1):91-6. PubMed ID: 16523432
[TBL] [Abstract][Full Text] [Related]
3. ACE inhibitors do not affect erythropoietin efficacy in haemodialysis patients.
Conlon PJ; Albers F; Butterly D; Schwab SJ
Nephrol Dial Transplant; 1994; 9(9):1358. PubMed ID: 7816313
[No Abstract] [Full Text] [Related]
4. Angiotensin converting enzyme inhibitors impair recombinant human erythropoietin induced erythropoiesis in patients with chronic renal failure.
Qureshi IZ; Abid K; Ambreen F; Qureshi AL
Saudi Med J; 2007 Feb; 28(2):193-6. PubMed ID: 17268695
[TBL] [Abstract][Full Text] [Related]
5. Intensity of hemodialysis and response to erythropoietin.
Kotanko P
N Engl J Med; 1996 Jun; 334(25):1670; author reply 1670-1. PubMed ID: 8628371
[No Abstract] [Full Text] [Related]
6. Integrated therapies including erythropoietin decrease the incidence of dialysis: lessons from mapping the incidence of end-stage renal disease in Japan.
Furumatsu Y; Nagasawa Y; Hamano T; Iwatani H; Iio K; Shoji T; Ito T; Tsubakihara Y; Imai E
Nephrol Dial Transplant; 2008 Mar; 23(3):984-90. PubMed ID: 17956890
[TBL] [Abstract][Full Text] [Related]
7. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
Han SW; Won YW; Yi JH; Kim HJ
Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
[TBL] [Abstract][Full Text] [Related]
8. Renin-angiotensin blockade reduces serum free testosterone in middle-aged men on haemodialysis and correlates with erythropoietin resistance.
DeLong M; Logan JL; Yong KC; Lien YH
Nephrol Dial Transplant; 2005 Mar; 20(3):585-90. PubMed ID: 15735242
[TBL] [Abstract][Full Text] [Related]
9. Pulse pressure and inhibition of renin-angiotensin system in chronic kidney disease.
Banerjee D; Brincat S; Gregson H; Contreras G; Streather C; Oliveira D; Nelson S
Nephrol Dial Transplant; 2006 Apr; 21(4):975-8. PubMed ID: 16384830
[TBL] [Abstract][Full Text] [Related]
10. [Physiopathology and therapy of chronic kidney failure].
Sakai O
Nihon Naika Gakkai Zasshi; 1995 Mar; 84(3):480-4. PubMed ID: 7751793
[No Abstract] [Full Text] [Related]
11. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease.
Berger AK; Duval S; Manske C; Vazquez G; Barber C; Miller L; Luepker RV
Am Heart J; 2007 Jun; 153(6):1064-73. PubMed ID: 17540211
[TBL] [Abstract][Full Text] [Related]
12. European best practice guidelines 14-16: inadequate response to epoetin.
Hörl WH; Jacobs C; Macdougall IC; Valderrábano F; Parrondo I; Thompson K; Carveth BG
Nephrol Dial Transplant; 2000; 15 Suppl 4():43-50. PubMed ID: 11052148
[No Abstract] [Full Text] [Related]
13. [Study of various factors that could have an impact on the treatment with erythropoietin of hemodialysis anemia].
Fernández-Gallego J; Ramos B; Ruiz A; Contreras J; Alvarez Bustos G; López de Novales E
Nefrologia; 2000; 20(2):164-70. PubMed ID: 10853198
[TBL] [Abstract][Full Text] [Related]
14. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
Pizzarelli F; David S; Sala P; Icardi A; Casani A
Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
[TBL] [Abstract][Full Text] [Related]
15. [Use of erythropoietin in patients with chronic renal insufficiency and in hemodialysis].
Cuero CJ; Pérez Guardia E; de Rivera C
Rev Med Panama; 1996; 21(1-2):55-9. PubMed ID: 8966240
[TBL] [Abstract][Full Text] [Related]
16. Responsiveness to erythropoietin and intrinsic inflammatory status in haemodialysis.
Romero R; Novoa D; Perez-Freiria A; Alonso R; Donapetry C; Sanchez-Guisande D
Nephrol Dial Transplant; 1994; 9(11):1696-7. PubMed ID: 7870370
[No Abstract] [Full Text] [Related]
17. ACE inhibitors do not decrease rHuEpo response in patients with end-stage renal failure.
Sánchez JA
Nephrol Dial Transplant; 1995; 10(8):1476-7. PubMed ID: 8538957
[No Abstract] [Full Text] [Related]
18. Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis.
Fang W; Oreopoulos DG; Bargman JM
Nephrol Dial Transplant; 2008 Nov; 23(11):3704-10. PubMed ID: 18567695
[TBL] [Abstract][Full Text] [Related]
19. [The effect of hemodialysis and continuous ambulatory peritoneal dialysis on renal anemia].
Stojimirović B; Grujić-Adanja G
Srp Arh Celok Lek; 1997; 125(5-6):163-7. PubMed ID: 9265238
[TBL] [Abstract][Full Text] [Related]
20. Can acidosis and hyperphosphataemia result in increased erythropoietin dosing in haemodialysis patients?
Diskin CJ; Stokes TJ; Dansby LM; Radcliff L; Carter TB
Nephrology (Carlton); 2006 Oct; 11(5):394-9. PubMed ID: 17014551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
